Skip to content

Treatment of atopic dermatitis in children by Homoeopathic medicines

An open label single arm prospective interventional study on the role of hahnemanns anti psoric medicines in children with Atopic Dermatitis - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110422
Enrollment
36
Registered
2026-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Homoeopathic anti psoric medicines: Individualized homoeopathic anti psoric medicine involves selection of a single remedy from the list of Hahnemanns anti psoric medicines as described

Sponsors

RBTS government homoeopathic medical college and hospital muzaffarpur bihar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who have been previously diagnosed with atopic dermatitis or clinically diagnosed at the time of enrolment based on hanifin and rajka criteria or UK Working party diagnostic criteria for atopic dermatitis Patients of both sexes between age group 2 to 17 years irrespective of religions and any socio economic status Patients or guardians willing to receive homeopathic treatment and adhere to follow up assessments Signed informed consent

Exclusion criteria

Exclusion criteria: Patients currently using systemic immunosuppressive therapies Patient having severe non treatable complication of atopic dermatitis Patient who do not take medicine and advice properly Patients or guardians unable to adhere to the study protocol or follow up schedule Patients with co existing skin conditions mimicking Atopic dermatitis Patient without written consent Patient who required emergency medical intervention

Design outcomes

Primary

MeasureTime frame
Changes in severity of Atopic Dermatitis assessed by SCORAD index from baseline to 12 weeksTimepoint: At Baseline and at 12 weeks after end of intervention period

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Md Makhdoom Azam

RBTS Government Homoeopathic Medical College and Hospital Ramdayalu Nagar Ramna Muzaffarpur

singh.katyayni@gmail.com7739560242

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026